Thema: US67577C1053
OCGN, US67577C1053
new-york-stock-exchange-1708834_1920.jpg - Foto: THN
Ocugen stock schedules two November gene therapy appearances
Ocugen stock is set for two November industry appearances focused on its modifier gene therapy platform. The events will feature CEO Shankar Musunuri.
ad-hoc-news.de, 30.10.26 19:30 Uhr
OCGN, US67577C1053
Noble Financial keeps USD 12.00 target for Ocugen stock
Ocugen booked USD 1.49 million in second-quarter 2026 revenue. Ocugen stock costs EUR 0.67 on October 27, 2026 at 8:05 p.m. CEST.
ad-hoc-news.de, 27.10.26 20:10 Uhr
OCGN, US67577C1053
Noble Financial keeps USD 12.00 target for Ocugen stock
Ocugen reports third-quarter results on November 4, 2026. Ocugen stock costs EUR 0.66 on October 24, 2026, down 9.59 percent versus the German close.
ad-hoc-news.de, 24.10.26 18:44 Uhr
OCGN, US67577C1053
H.C. Wainwright sets USD 10.00 target for Ocugen stock
Ocugen booked USD 1.49 million revenue in second-quarter 2026. Ocugen stock costs EUR 0.74 on October 20, 2026, while Nasdaq quotes USD 0.83.
ad-hoc-news.de, 20.10.26 18:47 Uhr
OCGN, US67577C1053
Ocugen stock faces December 22 vote on 250 million shares ...
Ocugen's Nasdaq price fell 4.10 percent to USD 0.78 on October 16, 2026. Ocugen stock stood at USD 0.78 after a USD 0.81 close.
ad-hoc-news.de, 17.10.26 19:49 Uhr
OCGN, US67577C1053
Ocugen stock gained 3.37 percent on October 6 as Europe ...
Ocugen stock's Q2 loss reached USD 0.07 per share versus USD 0.05 expected. Cash totaled USD 100.4 million on June 30, 2026, extending runway into 2028.
ad-hoc-news.de, 07.10.26 03:44 Uhr
Ocugen, Secures
Ocugen Secures Funding to Advance Gene Therapy Pipeline
